Abstract S2-06: Survival advantage of anastrozol compared to tamoxifen for lobular breast cancer in the ABCSG-8 study
Michael Knauer(Breast Center), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Martin Filipits(University of Vienna), Christian Fesl(Austrian Breast & Colorectal Cancer Study Group), Richard Greil(Paracelsus Medical University), Rupert Bartsch(Universitätszahnklinik Wien), Margaretha Rudas(Comprehensive Cancer Center Vienna), Christine Gruber(Central Institution for Meteorology and Geodynamics), Peter Dubsky(Hirslanden Klinik St. Anna), W. Kwasny(State Hospital), Brigitte Mlineritsch(Paracelsus Medical University), Otto Dietze(Medical University of Graz), Christian Singer, Herbert Stöger(Medical University of Graz), Günther Steger(Barwon Health), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), R. Jakesz(Comprehensive Cancer Center Vienna), Florian Fitzal
Cited by 21
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k